{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:57:27Z","timestamp":1791464247464,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejca.2025.115584","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:02:44Z","timestamp":1750168964000},"page":"115584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-3539","authenticated-orcid":false,"given":"Jonathan A.","family":"Ledermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-3225","authenticated-orcid":false,"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7194","authenticated-orcid":false,"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-715X","authenticated-orcid":false,"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne I.","family":"Weberpals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Clamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3121-4605","authenticated-orcid":false,"given":"Robert W.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita Amenedo","family":"Gancedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2689-8958","authenticated-orcid":false,"given":"Peter C.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-0177","authenticated-orcid":false,"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-803X","authenticated-orcid":false,"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Garc\u00eda-Donas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-1721","authenticated-orcid":false,"given":"Coriolan","family":"Lebreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-7586","authenticated-orcid":false,"given":"Iain A.","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4164-8788","authenticated-orcid":false,"given":"Lara","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Goble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115584_bib1","unstructured":"World Health Organization, International Agency for Research on Cancer (IARC). Global Cancer Observatory: GLOBOCAN 2020. https:\/\/gco.iarc.fr (accessed April 19, 2024)."},{"key":"10.1016\/j.ejca.2025.115584_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ctrv.2018.06.001","article-title":"Maintenance treatment of recurrent ovarian cancer: is it ready for prime time?","volume":"69","author":"DiSilvestro","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115584_bib3","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115584_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","article-title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Ledermann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2025.115584_bib7","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0090-8258(21)00693-4","article-title":"Long-term safety and secondary efficacy endpoints in the ENGOT-OV16\/NOVA phase III trial of niraparib in recurrent ovarian cancer","volume":"162","author":"Matulonis","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib10","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2025.115584_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115584_bib12","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115584_bib13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib15","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2025.115584_bib16","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115584_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","article-title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","volume":"167","author":"O\u2019Malley","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ygyno.2023.01.033","article-title":"Response to letter to the editor \u201cAML and MDS associated with PARP inhibitor treatment of ovarian cancer","volume":"171","author":"O\u2019Malley","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2025.115584_bib19","doi-asserted-by":"crossref","unstructured":"Matulonis U.A., Herrstedt J., Oza A., et al. Final overall survival and long-term safety in the ENGOT-OV16\/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer. Presented at Society of Gynecologic Oncology Annual Meeting; March 25-28, 2023; Tampa, FL, USA.","DOI":"10.1016\/j.ygyno.2023.06.508"},{"key":"10.1016\/j.ejca.2025.115584_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2022.11.027","article-title":"AML and MDS associated with PARP inhibitor treatment of ovarian cancer","volume":"171","author":"Armstrong","year":"2023","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:36:32Z","timestamp":1762342592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"alternative-id":["S0959804925003661"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115584","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115584"}}